Lindsley F. Kimball Research Institute
Shibo Jiang has not added Biography.
If you are Shibo Jiang and would like to personalize this page please email our Author Liaison for assistance.
Peptide and non-peptide HIV fusion inhibitors.
Current pharmaceutical design , 2002 | Pubmed ID: 11945159
Anti-HIV-1 activity of cellulose acetate phthalate: synergy with soluble CD4 and induction of "dead-end" gp41 six-helix bundles.
BMC infectious diseases Apr, 2002 | Pubmed ID: 11983022
Identification of inhibitors of the HIV-1 gp41 six-helix bundle formation from extracts of Chinese medicinal herbs Prunella vulgaris and Rhizoma cibotte.
Life sciences Aug, 2002 | Pubmed ID: 12151056
XTT formazan widely used to detect cell viability inhibits HIV type 1 infection in vitro by targeting gp41.
AIDS research and human retroviruses Sep, 2002 | Pubmed ID: 12396451
The in vitro and in vivo protective activity of monoclonal antibodies directed against Hantaan virus: potential application for immunotherapy and passive immunization.
Biochemical and biophysical research communications Nov, 2002 | Pubmed ID: 12408987
Design of a protein surface antagonist based on alpha-helix mimicry: inhibition of gp41 assembly and viral fusion.
Angewandte Chemie (International ed. in English) Jan, 2002 | Pubmed ID: 12491408
Automatic quantitation of HIV-1 mediated cell-to-cell fusion with a digital image analysis system (DIAS): application for rapid screening of HIV-1 fusion inhibitors.
Journal of virological methods Feb, 2003 | Pubmed ID: 12505629
Role of the fusion peptide and membrane-proximal domain in HIV-1 envelope glycoprotein-mediated membrane fusion.
Biochemistry Dec, 2003 | Pubmed ID: 14640682
Development of a cell-based enzyme-linked immunosorbent assay for high-throughput screening of HIV type 1 entry inhibitors targeting the coreceptor CXCR4.
AIDS research and human retroviruses Nov, 2003 | Pubmed ID: 14678601
Determination of the HIV-1 gp41 fusogenic core conformation modeled by synthetic peptides: applicable for identification of HIV-1 fusion inhibitors.
Peptides Sep, 2003 | Pubmed ID: 14706544
Rapid and automated fluorescence-linked immunosorbent assay for high-throughput screening of HIV-1 fusion inhibitors targeting gp41.
Journal of biomolecular screening Dec, 2003 | Pubmed ID: 14711394
Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusion-inducing conformational changes.
Journal of virology Mar, 2004 | Pubmed ID: 14963170
Synthesis and anti-HIV-1 activity of 4-[4-(4,6-bisphenylamino-triazin-2-ylamino)-5-methoxy-2-methylphenylazo]-5-hydroxynaphthalene-2,7-disulfonic acid and its derivatives.
Bioorganic & medicinal chemistry Mar, 2004 | Pubmed ID: 14980633
Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors.
Lancet Mar, 2004 | Pubmed ID: 15043961
Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways.
The Journal of pathology Jun, 2004 | Pubmed ID: 15141376
High throughput screening and characterization of HIV-1 entry inhibitors targeting gp41: theories and techniques.
Current pharmaceutical design , 2004 | Pubmed ID: 15180543
Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines.
Journal of immunology (Baltimore, Md. : 1950) Sep, 2004 | Pubmed ID: 15356154
Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine.
Biochemical and biophysical research communications Nov, 2004 | Pubmed ID: 15474494
N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion.
Antimicrobial agents and chemotherapy Nov, 2004 | Pubmed ID: 15504864
Mapping of antigenic sites on the nucleocapsid protein of the severe acute respiratory syndrome coronavirus.
Journal of clinical microbiology Nov, 2004 | Pubmed ID: 15528730
Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry.
Biochemical and biophysical research communications Dec, 2004 | Pubmed ID: 15530413
Different from the HIV fusion inhibitor C34, the anti-HIV drug Fuzeon (T-20) inhibits HIV-1 entry by targeting multiple sites in gp41 and gp120.
The Journal of biological chemistry Mar, 2005 | Pubmed ID: 15640162
Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines.
Virology Mar, 2005 | Pubmed ID: 15749124
Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies.
Journal of immunology (Baltimore, Md. : 1950) Apr, 2005 | Pubmed ID: 15814718
Theaflavin derivatives in black tea and catechin derivatives in green tea inhibit HIV-1 entry by targeting gp41.
Biochimica et biophysica acta May, 2005 | Pubmed ID: 15823507
rOv-ASP-1, a recombinant secreted protein of the helminth Onchocercavolvulus, is a potent adjuvant for inducing antibodies to ovalbumin, HIV-1 polypeptide and SARS-CoV peptide antigens.
Vaccine May, 2005 | Pubmed ID: 15837368
Combination of candidate microbicides cellulose acetate 1,2-benzenedicarboxylate and UC781 has synergistic and complementary effects against human immunodeficiency virus type 1 infection.
Antimicrobial agents and chemotherapy May, 2005 | Pubmed ID: 15855503
Chemoenzymatic synthesis of HIV-1 gp41 glycopeptides: effects of glycosylation on the anti-HIV activity and alpha-helix bundle-forming ability of peptide C34.
Chembiochem : a European journal of chemical biology Jun, 2005 | Pubmed ID: 15883971
Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.
Virology Sep, 2005 | Pubmed ID: 15996703
SARS vaccine development.
Emerging infectious diseases Jul, 2005 | Pubmed ID: 16022774
Vaccine design for severe acute respiratory syndrome coronavirus.
Viral immunology , 2005 | Pubmed ID: 16035944
Identification of immunodominant epitopes on the membrane protein of the severe acute respiratory syndrome-associated coronavirus.
Journal of clinical microbiology Aug, 2005 | Pubmed ID: 16081901
Neutralization of HIV-1 primary isolate by ELDKWA-specific murine monoclonal antibodies.
Immunobiology , 2005 | Pubmed ID: 16323702
The ribosomal protein L32-2 (RPL32-2) of S. pombe exhibits a novel extraribosomal function by acting as a potential transcriptional regulator.
FEBS letters Mar, 2006 | Pubmed ID: 16516201
硫代磷酸寡核苷酸通过阻止 gp41 核心形成抑制人体免疫缺陷病毒 1 型融合。
Antimicrobial agents and chemotherapy Apr, 2006 | Pubmed ID: 16569857
A single amino acid substitution (R441A) in the receptor-binding domain of SARS coronavirus spike protein disrupts the antigenic structure and binding activity.
Biochemical and biophysical research communications May, 2006 | Pubmed ID: 16615996
Theta-defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation.
The Journal of biological chemistry Jul, 2006 | Pubmed ID: 16648135
Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein.
Journal of immunology (Baltimore, Md. : 1950) May, 2006 | Pubmed ID: 16670317
Cellulose acetate 1,2-benzenedicarboxylate inhibits infection by cell-free and cell-associated primary HIV-1 isolates.
AIDS research and human retroviruses May, 2006 | Pubmed ID: 16706617
Antigenic properties of a transport-competent influenza HA/HIV Env chimeric protein.
Virology Aug, 2006 | Pubmed ID: 16725170
Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine.
Vaccine Jun, 2006 | Pubmed ID: 16725238
Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design.
Journal of virology Jun, 2006 | Pubmed ID: 16731915
Recombinant adeno-associated virus expressing the receptor-binding domain of severe acute respiratory syndrome coronavirus S protein elicits neutralizing antibodies: Implication for developing SARS vaccines.
Virology Sep, 2006 | Pubmed ID: 16793110
Evaluation of "credit card" libraries for inhibition of HIV-1 gp41 fusogenic core formation.
Journal of combinatorial chemistry Jul-Aug, 2006 | Pubmed ID: 16827565
Identification of a D-amino acid decapeptide HIV-1 entry inhibitor.
Biochemical and biophysical research communications Sep, 2006 | Pubmed ID: 16854380
Microbicides: stopping HIV at the gate.
Lancet Aug, 2006 | Pubmed ID: 16890813
Identification of the HIV-1 gp41 core-binding motif--HXXNPF.
FEBS letters Sep, 2006 | Pubmed ID: 16904109
China needs safe and effective microbicides for preventing sexual transmission of HIV.
The Lancet infectious diseases Nov, 2006 | Pubmed ID: 17067914
Selection of a novel gp41-specific HIV-1 neutralizing human antibody by competitive antigen panning.
Journal of immunological methods Dec, 2006 | Pubmed ID: 17078964
Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model.
Vaccine Apr, 2007 | Pubmed ID: 17092615
Polymorphisms of type I interferon receptor 1 promoter and their effects on chronic hepatitis B virus infection.
Journal of hepatology Feb, 2007 | Pubmed ID: 17125879
Identification of the HIV-1 gp41 core-binding motif in the scaffolding domain of caveolin-1.
The Journal of biological chemistry Mar, 2007 | Pubmed ID: 17197700
The mechanism by which molecules containing the HIV gp41 core-binding motif HXXNPF inhibit HIV-1 envelope glycoprotein-mediated syncytium formation.
The Biochemical journal May, 2007 | Pubmed ID: 17223796
HIV entry inhibitors targeting gp41: from polypeptides to small-molecule compounds.
Current pharmaceutical design , 2007 | Pubmed ID: 17269924
HIV gp41 C-terminal heptad repeat contains multifunctional domains. Relation to mechanisms of action of anti-HIV peptides.
The Journal of biological chemistry Mar, 2007 | Pubmed ID: 17276993
HIV-1 gp41 ectodomain enhances Cryptococcus neoformans binding to HBMEC.
Biochemical and biophysical research communications May, 2007 | Pubmed ID: 17400192
Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.
Cell Apr, 2007 | Pubmed ID: 17448989
Structure-based identification of small molecule compounds targeting cell cyclophilin A with anti-HIV-1 activity.
European journal of pharmacology Jun, 2007 | Pubmed ID: 17449029
Cleavage of spike protein of SARS coronavirus by protease factor Xa is associated with viral infectivity.
Biochemical and biophysical research communications Jul, 2007 | Pubmed ID: 17533109
Conserved residue Lys574 in the cavity of HIV-1 Gp41 coiled-coil domain is critical for six-helix bundle stability and virus entry.
The Journal of biological chemistry Aug, 2007 | Pubmed ID: 17616522
Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies.
Proceedings of the National Academy of Sciences of the United States of America Jul, 2007 | Pubmed ID: 17620608
The function of coreceptor as a basis for the kinetic dissection of HIV type 1 envelope protein-mediated cell fusion.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology Apr, 2008 | Pubmed ID: 18032634
Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.
Journal of immunology (Baltimore, Md. : 1950) Jan, 2008 | Pubmed ID: 18178835
Molecular modeling studies of N-substituted pyrrole derivatives--potential HIV-1 gp41 inhibitors.
Bioorganic & medicinal chemistry Mar, 2008 | Pubmed ID: 18226912
Extracellular matrix protein betaig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation.
Genes & development Feb, 2008 | Pubmed ID: 18245446
Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection.
Vaccine Mar, 2008 | Pubmed ID: 18289745
Development of subunit vaccines against severe acute respiratory syndrome.
Drugs of today (Barcelona, Spain : 1998) Jan, 2008 | Pubmed ID: 18301805
Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor.
The Journal of biological chemistry Apr, 2008 | Pubmed ID: 18303020
Interaction of HIV-1 gp41 core with NPF motif in Epsin: implication in endocytosis of HIV.
The Journal of biological chemistry May, 2008 | Pubmed ID: 18375383
Surface exposure of the HIV-1 env cytoplasmic tail LLP2 domain during the membrane fusion process: interaction with gp41 fusion core.
The Journal of biological chemistry Jun, 2008 | Pubmed ID: 18408000
Identification of a critical motif for the human immunodeficiency virus type 1 (HIV-1) gp41 core structure: implications for designing novel anti-HIV fusion inhibitors.
Journal of virology Jul, 2008 | Pubmed ID: 18417584
Cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody that recognizes a novel conformational epitope on gp41 and lacks reactivity against self-antigens.
Journal of virology Jul, 2008 | Pubmed ID: 18480433
Prolongation of corneal xenotransplant survival by T-cell vaccination-induced T-regulatory cells.
Xenotransplantation May-Jun, 2008 | Pubmed ID: 18611224
Rationally designed anti-HIV peptides containing multifunctional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitors.
The Journal of biological chemistry Oct, 2008 | Pubmed ID: 18662985
Evaluation of recombinant Onchocerca volvulus activation associated protein-1 (ASP-1) as a potent Th1-biased adjuvant with a panel of protein or peptide-based antigens and commercial inactivated vaccines.
Vaccine Sep, 2008 | Pubmed ID: 18675867
Novel anti-HIV peptides containing multiple copies of artificially designed heptad repeat motifs.
Biochemical and biophysical research communications Oct, 2008 | Pubmed ID: 18682248
Deletion of fusion peptide or destabilization of fusion core of HIV gp41 enhances antigenicity and immunogenicity of 4E10 epitope.
Biochemical and biophysical research communications Nov, 2008 | Pubmed ID: 18762167
Conserved salt bridge between the N- and C-terminal heptad repeat regions of the human immunodeficiency virus type 1 gp41 core structure is critical for virus entry and inhibition.
Journal of virology Nov, 2008 | Pubmed ID: 18768964
Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains.
Proceedings of the National Academy of Sciences of the United States of America Oct, 2008 | Pubmed ID: 18852475
Development and preclinical studies of broad-spectrum anti-HIV agent (3'R,4'R)-3-cyanomethyl-4-methyl-3',4'-di-O-(S)-camphanoyl-(+)-cis-khellactone (3-cyanomethyl-4-methyl-DCK).
Journal of medicinal chemistry Dec, 2008 | Pubmed ID: 19053755
Design, synthesis, and biological evaluation of N-carboxyphenylpyrrole derivatives as potent HIV fusion inhibitors targeting gp41.
Journal of medicinal chemistry Dec, 2008 | Pubmed ID: 19053778
Identification of critical antibody-binding sites in the HIV-1 gp41 six-helix bundle core as potential targets for HIV-1 fusion inhibitors.
Immunobiology , 2009 | Pubmed ID: 19159827
The spike protein of SARS-CoV--a target for vaccine and therapeutic development.
Nature reviews. Microbiology Mar, 2009 | Pubmed ID: 19198616
Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors.
AIDS (London, England) Mar, 2009 | Pubmed ID: 19242316
Recombinant Ov-ASP-1, a Th1-biased protein adjuvant derived from the helminth Onchocerca volvulus, can directly bind and activate antigen-presenting cells.
Journal of immunology (Baltimore, Md. : 1950) Apr, 2009 | Pubmed ID: 19299698
Antigenicity and immunogenicity of SARS-CoV S protein receptor-binding domain stably expressed in CHO cells.
Biochemical and biophysical research communications Jul, 2009 | Pubmed ID: 19422787
Phenotypic and genotypic characterization of human immunodeficiency virus type 1 CRF07_BC strains circulating in the Xinjiang Province of China.
Retrovirology , 2009 | Pubmed ID: 19442296
H3N2 猪流感病毒和事先的人类流感疫苗病毒之间高基因和抗原相似之处: 可能免疫压力驱动跨物种传播。
Biochemical and biophysical research communications Jul, 2009 | Pubmed ID: 19463787
Drug-resistant viruses may repair impaired fitness by mutations outside the drug target site.
Future microbiology Jun, 2009 | Pubmed ID: 19492961
Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains.
Journal of virology Aug, 2009 | Pubmed ID: 19493996
Discovery of diarylpyridine derivatives as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.
Bioorganic & medicinal chemistry letters Sep, 2009 | Pubmed ID: 19666220
Recombinant receptor-binding domain of SARS-CoV spike protein expressed in mammalian, insect and E. coli cells elicits potent neutralizing antibody and protective immunity.
Virology Oct, 2009 | Pubmed ID: 19683779
Design, synthesis, and structure-activity relationship of a novel series of 2-aryl 5-(4-oxo-3-phenethyl-2-thioxothiazolidinylidenemethyl)furans as HIV-1 entry inhibitors.
Journal of medicinal chemistry Dec, 2009 | Pubmed ID: 19746983
ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation.
Antimicrobial agents and chemotherapy Dec, 2009 | Pubmed ID: 19786602
Structure-based design, synthesis and biological evaluation of new N-carboxyphenylpyrrole derivatives as HIV fusion inhibitors targeting gp41.
Bioorganic & medicinal chemistry letters Jan, 2010 | Pubmed ID: 19932616
E14-F55 combination in M2 protein: a putative molecular determinant responsible for swine-origin influenza A virus transmission in humans.
PLoS currents , 2009 | Pubmed ID: 20029615
Research and development of universal influenza vaccines.
Microbes and infection / Institut Pasteur Apr, 2010 | Pubmed ID: 20079871
An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses.
Virology journal , 2010 | Pubmed ID: 20082709
Association of candidate susceptible loci with chronic infection with hepatitis B virus in a Chinese population.
Journal of medical virology Mar, 2010 | Pubmed ID: 20087947
HIV type 1 B'/C recombinant (CRF07_BC) in virologic noncontrollers elicits neutralizing antibodies against heterologous but not autologous viruses.
AIDS research and human retroviruses Feb, 2010 | Pubmed ID: 20156107
3-hydroxyphthalic anhydride-modified chicken ovalbumin exhibits potent and broad anti-HIV-1 activity: a potential microbicide for preventing sexual transmission of HIV-1.
Antimicrobial agents and chemotherapy May, 2010 | Pubmed ID: 20194691
HIV-1 gp41 fusion intermediate: a target for HIV therapeutics.
Journal of the Formosan Medical Association = Taiwan yi zhi Feb, 2010 | Pubmed ID: 20206833
Genomic signature and mutation trend analysis of pandemic (H1N1) 2009 influenza A virus.
PloS one , 2010 | Pubmed ID: 20221396
Potent and broad neutralizing activity of a single chain antibody fragment against cell-free and cell-associated HIV-1.
mAbs May-Jun, 2010 | Pubmed ID: 20305395
A 219-mer CHO-expressing receptor-binding domain of SARS-CoV S protein induces potent immune responses and protective immunity.
Viral immunology Apr, 2010 | Pubmed ID: 20374001
Maleic anhydride-modified chicken ovalbumin as an effective and inexpensive anti-HIV microbicide candidate for prevention of HIV sexual transmission.
Retrovirology , 2010 | Pubmed ID: 20420669
Diarylaniline derivatives as a distinct class of HIV-1 non-nucleoside reverse transcriptase inhibitors.
Journal of medicinal chemistry Jul, 2010 | Pubmed ID: 20527972
Novel recombinant engineered gp41 N-terminal heptad repeat trimers and their potential as anti-HIV-1 therapeutics or microbicides.
The Journal of biological chemistry Aug, 2010 | Pubmed ID: 20538590
Identification of a gp41 core-binding molecule with homologous sequence of human TNNI3K-like protein as a novel human immunodeficiency virus type 1 entry inhibitor.
Journal of virology Sep, 2010 | Pubmed ID: 20592080
Tricyclononene carboxamide derivatives as novel anti-HIV-1 agents.
European journal of medicinal chemistry Sep, 2010 | Pubmed ID: 20598780
A recombinant mimetics of the HIV-1 gp41 prehairpin fusion intermediate fused with human IgG Fc fragment elicits neutralizing antibody response in the vaccinated mice.
Biochemical and biophysical research communications Jul, 2010 | Pubmed ID: 20599765
Development of a safe and convenient neutralization assay for rapid screening of influenza HA-specific neutralizing monoclonal antibodies.
Biochemical and biophysical research communications Jul, 2010 | Pubmed ID: 20617558
An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus.
Virology journal , 2010 | Pubmed ID: 20624292
Development of a safe and convenient neutralization assay for rapid screening of influenza HA-specific neutralizing monoclonal antibodies.
Biochemical and biophysical research communications Jun, 2010 | Pubmed ID: 20685351
A novel strategy for rapid construction of libraries of full-length antibodies highly expressed on mammalian cell surfaces.
Acta biochimica et biophysica Sinica Aug, 2010 | Pubmed ID: 20705599
Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant.
Vaccine Oct, 2010 | Pubmed ID: 20732469
Development of peptide and small-molecule HIV-1 fusion inhibitors that target gp41.
ChemMedChem Nov, 2010 | Pubmed ID: 20845360
Potent and persistent antibody responses against the receptor-binding domain of SARS-CoV spike protein in recovered patients.
Virology journal , 2010 | Pubmed ID: 21047436
Design, Synthesis, and Evaluation of Diarylpyridines and Diarylanilines as Potent Non-nucleoside HIV-1 Reverse Transcriptase Inhibitors.
Journal of medicinal chemistry Nov, 2010 | Pubmed ID: 21049929
In vitro selection and characterization of HIV-1 variants with increased resistance to sifuvirtide, a novel HIV-1 fusion inhibitor.
The Journal of biological chemistry Feb, 2011 | Pubmed ID: 21098485
Design, synthesis, and biological activity of novel 5-((arylfuran/1H-pyrrol-2-yl)methylene)-2-thioxo-3-(3-(trifluoromethyl)phenyl)thiazolidin-4-ones as HIV-1 fusion inhibitors targeting gp41.
Journal of medicinal chemistry Jan, 2011 | Pubmed ID: 21190369
Roles of the hemagglutinin of influenza A virus in viral entry and development of antiviral therapeutics and vaccines.
Protein & cell Apr, 2010 | Pubmed ID: 21203946
Combinations of 3-hydroxyphthalic anhydride-modified ovalbumin with antiretroviral drug-based microbicide candidates display synergistic and complementary effects against HIV-1 infection.
Journal of acquired immune deficiency syndromes (1999) Apr, 2011 | Pubmed ID: 21239999
Four-way ligation for construction of a mammalian cell-based full-length antibody display library.
Acta biochimica et biophysica Sinica Mar, 2011 | Pubmed ID: 21257624
HIV-associated dementia in the era of highly active antiretroviral therapy (HAART).
Microbes and infection / Institut Pasteur May, 2011 | Pubmed ID: 21262373
A recombinant vaccine of H5N1 HA1 fused with foldon and human IgG Fc induced complete cross-clade protection against divergent H5N1 viruses.
PloS one , 2011 | Pubmed ID: 21304591
Discovery of a potent peptidic cyclophilin A inhibitor Trp-Gly-Pro.
European journal of medicinal chemistry May, 2011 | Pubmed ID: 21396746
Susceptibility of HIV-1 subtypes B', CRF07_BC and CRF01_AE that are predominantly circulating in China to HIV-1 entry inhibitors.
PloS one , 2011 | Pubmed ID: 21412427
Complement inhibition alleviates paraquat-induced acute lung injury.
American journal of respiratory cell and molecular biology Oct, 2011 | Pubmed ID: 21421909
HIV-1 gp41 core with exposed membrane-proximal external region inducing broad HIV-1 neutralizing antibodies.
PloS one , 2011 | Pubmed ID: 21483871
CL-385319 inhibits H5N1 avian influenza A virus infection by blocking viral entry.
European journal of pharmacology Jun, 2011 | Pubmed ID: 21536025
HIV-1 gp41 ectodomain enhances Cryptococcus neoformans binding to human brain microvascular endothelial cells via gp41 core-induced membrane activities.
The Biochemical journal Sep, 2011 | Pubmed ID: 21668410
An amphiphilic conjugate approach toward the design and synthesis of betulinic acid-polyphenol conjugates as inhibitors of the HIV-1 gp41 fusion core formation.
ChemMedChem Sep, 2011 | Pubmed ID: 21688394
A novel chimeric protein-based HIV-1 fusion inhibitor targeting gp41 glycoprotein with high potency and stability.
The Journal of biological chemistry Aug, 2011 | Pubmed ID: 21690094
Heteromeric assembled polypeptidic artificial hydrolases with a six-helical bundle scaffold.
Chembiochem : a European journal of chemical biology Nov, 2011 | Pubmed ID: 21957084
Design, synthesis, and biological activity of a novel series of 2,5-disubstituted furans/pyrroles as HIV-1 fusion inhibitors targeting gp41.
Bioorganic & medicinal chemistry letters Nov, 2011 | Pubmed ID: 21978673
Mutations of Gln64 in the HIV-1 gp41 N-terminal heptad repeat render viruses resistant to peptide HIV fusion inhibitors targeting the gp41 pocket.
Journal of virology Jan, 2012 | Pubmed ID: 22013063
Design, synthesis and biological evaluation of 3-substituted 2,5-dimethyl-N-(3-(1H-tetrazol-5-yl)phenyl)pyrroles as novel potential HIV-1 gp41 inhibitors.
Bioorganic & medicinal chemistry Nov, 2011 | Pubmed ID: 22014749
HIV-1 glycoprotein 41 ectodomain induces activation of the CD74 protein-mediated extracellular signal-regulated kinase/mitogen-activated protein kinase pathway to enhance viral infection.
The Journal of biological chemistry Dec, 2011 | Pubmed ID: 22039051
Interactions between different generation HIV-1 fusion inhibitors and the putative mechanism underlying the synergistic anti-HIV-1 effect resulting from their combination.
The FASEB journal : official publication of the Federation of American Societies for Experimental Biology Nov, 2011 | Pubmed ID: 22085645
A natural theaflavins preparation inhibits HIV-1 infection by targeting the entry step: Potential applications for preventing HIV-1 infection.
Fitoterapia Mar, 2012 | Pubmed ID: 22155187
Identification of HBsAg-specific antibodies from a mammalian cell displayed full-length human antibody library of healthy immunized donor.
Cellular & molecular immunology Dec, 2011 | Pubmed ID: 22179672
Design, Synthesis and Biological Evaluation of 1-[(2-benzyloxyl/alkoxyl) methyl]-5-halo-6-aryluracils as Potent HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Improved Drug Resistance Profile.
Journal of medicinal chemistry Jan, 2012 | Pubmed ID: 22283377
What can academia learn from XMRV studies?
Nature reviews. Urology Feb, 2012 | Pubmed ID: 22331091
ÜBER JoVE
Copyright © 2024 MyJoVE Corporation. Alle Rechte vorbehalten